This datum, also confirmed in other studies [9], [17], [21], is of major significance, given that the adiponectin reduction is a key player in the development of cardiovascular complication in DM2, because it is the only known protective adipocytokine with insulin-sensitizing, anti-inflammatory and anti-atherogenic properties [29], [37], [38]. Here, ADIPOQ is linked to myotonic dystrophy type 2.